Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY 2395840 in Healthy Men
NCT05517746Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fulmetibant in endometriosis (12 arms), sponsored by Bayer. Primary endpoints: Number of participants with treatment-emergent adverse events and Number of participants with treatment-emergent adverse events, categorized by severity. Started Dec 2019; status: completed.
02
Drugs
fulmetibant
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT05517746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517746.